Physician profile
John P Stein
NPI 1629143219
$29,440.76
in general payments reported to CMS, 2019-2025
60 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $1,754 · 2021: $3,174 · 2022: $1,292 · 2023: $2,265 · 2024: $1,782 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,390 · Education: $266 · Entertainment: $15.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,390.39 |
| Education | $265.98 |
| Entertainment | $15.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16,644.29 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $3,449.01 | 2020-2025 | Nexletol |
| Abbvie INC. | $1,334.73 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $828.81 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $768.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $572.93 | 2019-2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $518.66 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $420.01 | 2019-2021 | |
| Neos Therapeutics, LP | $359.98 | 2019-2025 | Adzenys Xr-Odt |
| Allergan, INC. | $348.79 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $340.70 | 2022-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $282.10 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.44 | 2023-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $198.42 | 2022-2025 | |
| Tris Pharma INC | $191.92 | 2022-2025 | Dyanavel Xr |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $190.64 | 2025 | Veozah |
| Vanda Pharmaceuticals INC. | $186.68 | 2024-2025 | Fanapt |
| Corium, LLC | $180.82 | 2023-2024 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $176.01 | 2019-2021 | |
| Horizon Therapeutics Plc | $139.31 | 2019-2020 | |
| Noven Therapeutics, LLC | $135.03 | 2024 | Xelstrym |
| Bayer Healthcare Pharmaceuticals INC. | $120.35 | 2022 | |
| Noven Pharmaceuticals, INC. | $116.92 | 2023-2024 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $115.41 | 2022-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $110.17 | 2019-2024 | |
| Rhythm Pharmaceuticals, INC. | $107.70 | 2023 | Imcivree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.79 | 2020-2025 | Xifaxan, Ibschek |
| Merck Sharp & Dohme LLC | $86.29 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Sunovion Pharmaceuticals INC. | $76.09 | 2021-2022 | |
| Eisai INC. | $76.06 | 2020-2024 | |
| Antares Pharma, INC. | $75.00 | 2025 | Xyosted |
| Glaxosmithkline, LLC. | $73.74 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $69.15 | 2019 | |
| Bausch Health US, LLC | $66.51 | 2022-2024 | Wellbutrin, Aplenzin |
| Adlon Therapeutics L.P. | $65.54 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $63.35 | 2023-2024 | Edarbi, Horizant, Horizant |
| Lundbeck LLC | $57.52 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $54.09 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $48.64 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $47.11 | 2019-2020 | |
| Pfizer INC. | $44.46 | 2023-2025 | |
| Cleerly, INC. | $36.81 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Almatica Pharma LLC | $34.94 | 2024-2025 | Loreev Xr |
| Phathom Pharmaceuticals, INC. | $28.50 | 2024 | Voquezna |
| Abbott Laboratories | $27.93 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $26.50 | 2019-2021 | |
| Radius Health, INC. | $26.41 | 2019 | |
| Nevro Corp. | $21.74 | 2022 | |
| Shire North American Group INC | $20.43 | 2019 | |
| Itamar Medical INC | $18.00 | 2025 | Watchpatone |
| Collegium Pharmaceutical, INC. | $17.00 | 2025 | Jornay Pm |
| Genentech USA, INC. | $16.52 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.25 | 2021 | |
| Ge Healthcare | $15.73 | 2022 | |
| Exact Sciences Corporation | $15.45 | 2023 | Cologuard Collection Kit |
| Optos, INC. | $15.28 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.45 | 2020 | |
| Neuronetics, INC. | $13.01 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.89 | 2020 | |
| Travere Therapeutics, INC. | $6.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.